Work

An experimental MODEL study to investigate the pathogenesis of oxaliplatin-induced liver injury.

Year: 2013
Type: conference-abstract
Abstract: 184 Background: Oxaliplatin based chemotherapy is widely utilized pre-operatively in patients with colorectal liver metastases. Its use is associated with injury to the liver in the form of sinusoidal obstruction syndrome (SOS) the presence of which can have a negative impact on surgical outcomes. The pathogenesis of this condition is poorly understood. Methods: C57Bl/6 mice (n=10 per group) were treated with 5-FU/oxaliplatin/folinic acid chemotherapy (FOLFOX) weekly for 5 weeks or their respective vehicle controls. Animals were culled one week following the final treatment and liver tissue harvested for histological and biochemical analysis. mRNA was extracted from snap frozen liver and subject to genome wide expression analysis the results of which were confirmed using qRT-PCR. To determine the effect of background steatosis on the development of liver injury the experiment was repeated using mice maintained on a high fat diet. To assess the ability of antioxidants to prevent SOS development diet was supplemented with 3% butylated hydroxyanisole (BHA). Results: H&E stained tissue sections confirmed the presence of SOS in all FOLFOX treated animals. Microarray identified changes in expression of over 604 genes in the liver of animals with FOLFOX induced SOS. In particular there was increased expression of genes implicated in oxidative stress (e.g. Metallothionein 1; 22 fold; p<0.001), cell cycle arrest (e.g. p21; 21 fold; p<0.001) and angiogenesis (VEGF-A; 2 fold; p<0.001). Administration of the antioxidant BHA alongside chemotherapy prevented the development of SOS confirming the role of oxidative stress in the pathogenesis of this condition. There was down regulation of a number of genes implicated in fatty acid synthesis (e.g. FASN; 8 fold; p<0.001). In support of this mice maintained on a high fat diet treated with FOLFOX do not develop steatosis unlike those treated with vehicle alone. Conclusions: FOLFOX chemotherapy is specifically associated with SOS and not hepatic steatosis. We have identified some of the molecular pathways involved in the pathogenesis of this condition. Manipulation of these pathways may be of therapeutic potential in preventing the development of chemotherapy-associated liver injury.
Language: English
Subfield: Pharmacology
Open Access status: green
OpenAlex ID: W2419350323
Cites:
Cited by:
Related to: 10